StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

Equities researchers at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN) in a research report issued to clients and investors on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.

Lipocine Stock Down 1.8 %

LPCN stock opened at $4.37 on Friday. The stock has a 50-day simple moving average of $4.88 and a two-hundred day simple moving average of $5.00. The firm has a market capitalization of $23.38 million, a PE ratio of -5.75 and a beta of 1.23. Lipocine has a twelve month low of $3.20 and a twelve month high of $11.79.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. On average, equities research analysts anticipate that Lipocine will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.